EWA
AKTX

EverSource Wealth Advisors’s Akari Therapeutics AKTX Stock Holding History

EverSource Wealth Advisors’s Portfolio AKTX Stock Details AKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-1
Closed -$44 – 4276
2025
Q3 		$44 Sell
1
-108
-99% -$4.2K ﹤0.01% 4263
2025
Q2 		$5.12K Buy
+109
New +$5.5K ﹤0.01% 3152

Other funds holding AKTX

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
CAM
Cresset Asset Management Chicago, Illinois $23.1B AUM 27.04% 1-Year Est. Return
WAM
Warberg Asset Management Winnetka, Illinois $600M AUM 23.37% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $103B AUM 28.65% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
SP
SmartHarvest Portfolios Poulsbo, Washington $309M AUM
CAMG
CWA Asset Management Group Naples, Florida $3.28B AUM 34.07% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

EverSource Wealth Advisors's AKTX Position: Q4 2025 in Review

EverSource Wealth Advisors sold out of Akari Therapeutics (AKTX) in Q4 2025, closing a stake of 1 share — an estimated $44 sold.

EverSource Wealth Advisors first reported a position in AKTX in Q2 2025 and held it in 2 quarters. The position peaked at $5.12K in Q2 2025. 19 funds tracked by Wall St. Rank hold AKTX as of Q4 2025.

  • EverSource Wealth Advisors reported no remaining Akari Therapeutics position as of Q4 2025 after selling out during the quarter.
  • EverSource Wealth Advisors sold 1 Akari Therapeutics share in Q4 2025, an estimated $44.
  • EverSource Wealth Advisors first reported a position in Akari Therapeutics in Q2 2025 and held it in 2 quarters.
  • EverSource Wealth Advisors's Akari Therapeutics position peaked at $5.12K in Q2 2025.
  • 19 funds tracked by Wall St. Rank held Akari Therapeutics as of Q4 2025.

Based on EverSource Wealth Advisors's 13F filing for Q4 2025, filed 6 Feb 2026.